Three new drug indications physicians and pharmacists should know about

Padcevenfortumab vedotin for injection, Seagen Canada.NEW INDICATION Treatment of unresectable locally advanced or metastatic urothelial cancer, in combination with pembrolizumab, in adults with no prior systemic therapy for metastatic urothelial cancer. (Also approved earlier as a single agent for the treatment of unresectable locally advanced or metastatic urothelial cancer in adults who have previously received a platinum-containing chemotherapy and programmed death receptor-1 [PD-1] or programmed death-ligand 1 [PD-L1] inhibitor therapy.)DOSAGE When given in combination with pembrolizumab, the recommended dose of enfortumab vedotin is 1.25 mg/kg (up to a maximum of 125 mg for patients ≥100 kg) administered as an IV infusion over 30 minutes on Days 1 and 8 of a 21-day cycle, until disease progression or unacceptable toxicity occurs. Administer Padcev before pembrolizumab when given on the same day. Allow for an interval of 30 minutes between infusions (for at least Cycle 1, Day 1); this can subsequently be reduced to 15 minutes if well tolerated.Vabysmofaricimab solution for intravitreal injection, Hoffmann-La Roche.NEW INDICATION Treatment of macular edema secondary to retinal vein occlusion. (Also approved earlier for treatment of neovascular [wet] age-related macular degeneration and for the treatment of diabetic macular edema.)DOSAGE Macular edema secondary to retinal vein occlusion: 6 mg (0.05 mL) administered by intravitreal injection every four weeks for six months.Xydalbadalbavancin for injection, Paladin.EXPANDED INDICATION Now indicated for treatment of adults and children aged three months or older with acute bacterial skin and skin structure infections caused by susceptible isolates of the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius, Streptococcus constellatus) and Enterococcus faecalis (vancomycin-susceptible strains). (Formerly indicated for this use in adults only.)DOSAGE Children≥ 3 months to < 6 years of age: A single dose of 22.5 mg/kg (maximum of 1500 mg). Children ≥ 6 years to < 18 years of age: A single dose of 18 mg/kg (maximum of 1500 mg). Administer by IV infusion over 30 minutes.

Three new drug indications physicians and pharmacists should know about

Register for free access or login.

Related Topics